预约演示
更新于：2025-07-21
Famotidine
法莫替丁
更新于：2025-07-21
概要
基本信息
简介法莫替丁是一种药物，可以帮助患有胃炎和消化性溃疡等胃病的人。它属于一组称为 H2 受体拮抗剂的药物，其作用是阻止胃产生过多的酸。当胃酸过多时，人们会感到很痛，如胃灼热或消化不良。法莫替丁真的很擅长减少胃酸，让人感觉更好。它有不同的形式，如药片和注射剂，因此人们可以选择最适合自己的方式。 Bausch Health Americas 于 1986 年生产了法莫替丁，此后被很多人使用。人们应该确保按照医生的指示服用法莫替丁，以确保其正常工作并避免任何副作用。 |
药物类型 小分子化药 |
别名 (1-Amino-3-(((2-((diaminomethylene)amino)-4-thiazolyl)methyl)thio)propylidene)sulfamide、3-(((2-((Aminoiminomethyl)amino)-4-thiazolyl)methyl)thio)-N-(aminosulfonyl)propanimidamide、3-(((2-((Diaminomethylene)amino)-4-thiazolyl)methyl)thio)-N(sup 2)-sulfamoylpropionamidine + [40] |
作用方式 拮抗剂 |
作用机制 H2 receptor拮抗剂(组胺H2受体拮抗剂) |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C8H15N7O2S3 |
InChIKeyXUFQPHANEAPEMJ-UHFFFAOYSA-N |
CAS号76824-35-6 |
关联
147
项与 法莫替丁 相关的临床试验NCT06507904
A Phase 1, Randomized, Crossover Design Study to Assess Palatability of Osivelotor (PF-07940367) Pediatric Formulations With Dosing Vehicle (Part 1) and Randomized, Single-Dose, Parallel Design Study to Estimate Relative Bioavailability of Osivelotor Pediatric Formulation With Dosing Vehicle and With Water Compared to Clinical Tablet Formulation, and Effect of Food and/or Acid-Reducing Agent On Bioavailability In Healthy Adult Participants (Part 2)
NCT07018635
An Open-Label Study to Assess the Effect of Itraconazole, Rifampin, and Acid-Reducing Agents on INCB161734 Pharmacokinetics When Administered Orally in Healthy Participants
NCT06819670
A Multicenter Pilot Clinical Trial to Prevent Infantile Spasms Relapse
100 项与 法莫替丁 相关的临床结果
登录后查看更多信息
100 项与 法莫替丁 相关的转化医学
登录后查看更多信息
100 项与 法莫替丁 相关的专利（医药）
登录后查看更多信息
4,588
项与 法莫替丁 相关的文献（医药）2026-04-01DEN open
Olmesartan‐induced gastritis with no lower gastrointestinal symptoms: A case report
Article
作者: Kamiyama, Miki ; Ochi, Masahiro ; Kosaka, Satoshi
Abstract:
A 74‐year‐old man with decreased appetite, weight, and heartburn was referred to our hospital. His medications included olmesartan. Esophagogastroduodenoscopy (EGD) revealed antral‐dominant erosive gastritis and nodular mucosa. A gastric biopsy revealed inflammatory cell infiltration. The serum anti‐Helicobacter pylori immunoglobulin G antibody test result was negative. Famotidine was ineffective in relieving his symptoms, and esomeprazole failed to prevent overt gastric bleeding, which required endoscopic hemostasis. The working diagnosis was drug‐induced gastritis, particularly olmesartan‐induced gastritis. His appetite loss started to improve within a week of olmesartan withdrawal. The erosions healed on EGD 2 months later. Over the next 10 months, he remained in his usual state until olmesartan was inadvertently administered. Subsequent EGD revealed a mild gastritis relapse. We diagnosed olmesartan‐induced gastritis and discontinued olmesartan treatment. Mucosal healing was confirmed by EGD 1 year later. Olmesartan is known to cause angiotensin II receptor blocker‐induced enteropathy. Although angiotensin II receptor blocker‐induced enteropathy affects the stomach, angiotensin II receptor blocker‐induced gastritis without lower gastrointestinal symptoms is rare. The characteristic endoscopic appearance may provide a clue to the correct diagnosis.
2025-08-01Asia-Pacific Journal of Clinical Oncology
Evaluating the Effect of Oral Famotidine in Preventing Hypersensitivity Reactions in Individuals Receiving Platinum‐Based Agents or Taxanes
Article
作者: Shaseb, Elnaz ; Tohidifar, Faraz ; Beheshtirouy, Samineh ; Sarbakhsh, Parvin ; Ghaffary, Saba ; Mohammadzadeh, Mohammad
ABSTRACT:
Introduction:
Hypersensitivity reactions (HSRs), an unpredictable and sometimes harmful reaction, may hamper the effectiveness of chemotherapy and lead to the need for drug switching. The recall of ranitidine from the drug market due to the N‐nitrosodimethylamine production necessitates the identification of a proper alternative for the prevention of HSRs. Our study aimed to evaluate the efficacy of oral famotidine in the prevention of HSRs in patients who received chemotherapy agents, particularly platinum‐based and taxanes.
Methods:
A total of 426 patients who were treated with platinum‐based agents or taxanes as part of their regimen were divided into two groups. The famotidine group, including 213 patients, received the standard premedication along with an oral dose of 40 mg famotidine the night before and 1 h prior to the chemotherapy session. The control group, also including 213 patients, received only the standard premedication without famotidine.
Results:
Based on the results of this study, six patients in the control group experienced HSRs with a range of varying severities. No HSRs were observed by any of the patients in the famotidine group (p‐value = 0.022).
Conclusion:
Administration of oral famotidine is beneficial in preventing chemotherapy‐induced HSRs.
Clinical Trial Registration:
It was also registered with the Iran Clinical Trial Centre under code IRCT20160310026998N13.
2025-08-01ANIMAL REPRODUCTION SCIENCE
Effects of semen collection methods on sperm quality and metabolite profile in goat seminal plasma: Comparing between artificial vagina and electro-ejaculator techniques
Article
作者: Quan, Guobo ; Wu, Guoquan ; Li, Chunyan ; Larbi, Allai ; Liang, Jiachong ; Bouabid, Badaoui ; Lv, Chunrong
This study compared two semen collection methods-artificial vagina (AV) and electro-ejaculator (EE)-to evaluate their effects on sperm quality and the metabolomic profile of goat seminal plasma (SP). Semen samples were analyzed for sperm characteristics, and SP was assessed using ultra-performance liquid chromatography-electrospray ionization quadrupole Orbitrap mass spectrometry. Sperm collected via AV showed lower ejaculate volume but significantly higher concentration and motility than EE. Metabolomic profiling revealed 568 and 350 metabolites in positive and negative ion modes, respectively, with 105 and 77 showing significant differential expression. In the negative ion mode, metabolites such as bezafibrate, phosphatidylinositol 16 and 18, and benzothiazoline were down-regulated in AV, while docosahexaenoic acid, arachidonic acid, phosphatidylcholine, rutin, pyruvate, famotidine, and citrate were up-regulated. In the positive ion mode, metabolites including astaxanthin, lapachol, and 3-acetylaconitine were down-regulated, while mannitol, choline, L-carnitine, and indirubin were up-regulated in AV. KEGG pathway enrichment showed 30 significantly altered pathways. This is the first study to assess the impact of AV and EE on the metabolomic profile of goat SP. The identified metabolites serve as promising biomarkers for evaluating sperm quality and assessing reproductive potential, with implications for improving semen collection techniques and conserving genetic resources.
100 项与 法莫替丁 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 糜烂性食管炎 | 美国 | 2025-07-16 | |
| 食管溃疡 | 澳大利亚 | 2003-04-08 | |
| 急性胃炎 | 日本 | 2000-03-15 | |
| 吻合口溃疡 | 日本 | 2000-03-15 | |
| 慢性胃炎 | 日本 | 2000-03-15 | |
| 反流性食管炎 | 日本 | 2000-03-15 | |
| 出血性胃炎 | 日本 | 2000-03-15 | |
| 胃溃疡 | 日本 | 2000-03-15 | |
| 应激性溃疡 | 日本 | 2000-03-15 | |
| 上消化道出血 | 日本 | 2000-03-15 | |
| 消化道出血 | 中国 | - | 1996-01-01 |
| 胃炎 | 日本 | 1988-12-27 | |
| 消化性溃疡 | 日本 | 1988-12-10 | |
| 角膜溃疡 | 美国 | 1986-10-15 | |
| 十二指肠溃疡 | 美国 | 1986-10-15 | |
| 食管炎 | 美国 | 1986-10-15 | |
| 良性胃溃疡 | 美国 | 1986-10-15 | |
| 胃食管反流 | 美国 | 1986-10-15 | |
| 多发性内分泌瘤病 | 美国 | 1986-10-15 | |
| 溃疡 | 美国 | 1986-10-15 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 非糜烂性胃食管反流病 | 临床3期 | 日本 | 2005-09-01 | |
| HIV血清阳性 | 临床1期 | - | 2008-06-01 | |
| 胃灼热 | 临床1期 | - | 2006-08-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 5 | (HRA Treatment Arm) | 觸鬱壓壓繭淵繭廠淵積 = 鑰壓壓憲築製選糧廠壓 簾積遞願餘襯選鹹壓蓋 (壓艱襯壓齋遞餘醖簾壓, 夢蓋憲築鬱廠積構構鏇 ~ 襯鹹醖衊鹽鏇鬱範繭鏇) 更多 | - | 2025-07-17 | ||
Famotidine Placebo (Placebo Arm) | 觸鬱壓壓繭淵繭廠淵積 = 網齋齋淵鹽醖艱憲廠鹹 簾積遞願餘襯選鹹壓蓋 (壓艱襯壓齋遞餘醖簾壓, 鑰鹹鏇餘蓋糧遞顧襯鑰 ~ 襯膚襯鹽膚糧壓鑰蓋淵) 更多 | ||||||
N/A | - | 構糧夢願願繭艱願範繭(願網製醖顧衊糧餘範願) = 鏇鹹壓鹹艱廠齋夢製網 積蓋窪廠顧廠選鏇醖鹹 (網夢遞餘獵製繭獵艱遞 ) | - | 2025-05-16 | |||
临床2期 | 72 | Adjuvant RT+Nivolumab (Single Modality De-escalation Arm (SDA)) | 艱膚蓋襯廠齋襯廠鏇壓 = 鹽壓鏇蓋簾鏇襯夢選鬱 構衊鑰願遞糧製鏇襯窪 (鹽糧憲積觸鬱鬱鏇簾範, 簾鏇蓋構糧鬱獵觸餘繭 ~ 顧遞艱鬱獵夢廠鹹醖醖) 更多 | - | 2025-05-06 | ||
Chemoradiotherapy+Nivolumab+Dexamethasone+Paclitaxel+hydroxyurea+cisplatin+Famotidine+Diphenhydramine+5-FU (Intermediate De-escalation Arm (IDA)) | 艱膚蓋襯廠齋襯廠鏇壓 = 鏇膚廠膚範鬱窪襯鹽積 構衊鑰願遞糧製鏇襯窪 (鹽糧憲積觸鬱鬱鏇簾範, 選遞壓鬱醖膚鑰鹽選鹽 ~ 糧廠夢選觸窪鏇廠簾網) 更多 | ||||||
临床2期 | 80 | (Famotidine) | 觸壓餘壓淵鏇艱積夢襯(積製鏇淵淵獵築壓簾鑰) = 淵壓網願糧顧窪襯夢獵 艱簾夢構襯齋鬱襯築選 (鑰構獵製窪鑰積遞積願, 憲遞觸顧繭繭餘鹽膚醖 ~ 繭構齋網積鹽蓋繭簾憲) 更多 | - | 2024-08-09 | ||
Placebo (Placebo) | 觸壓餘壓淵鏇艱積夢襯(積製鏇淵淵獵築壓簾鑰) = 鬱構齋積艱鏇積餘襯齋 艱簾夢構襯齋鬱襯築選 (鑰構獵製窪鑰積遞積願, 鹽膚糧網鑰製襯鏇鏇膚 ~ 廠蓋獵窪鹽艱積構簾簾) 更多 | ||||||
临床2期 | 4 | (Group 1 (Study Product)) | 膚膚構遞鬱願遞淵選願 = 廠製窪觸鹽顧範襯願獵 鹹繭餘壓醖鹽鹹遞夢顧 (築蓋製蓋範齋衊簾鑰糧, 製獵簾衊鬱觸膚簾網鑰 ~ 齋窪簾簾築遞願範襯繭) 更多 | - | 2024-07-09 | ||
Placebo (Group 2 (Reference Therapy)) | 膚膚構遞鬱願遞淵選願 = 夢壓醖夢壓鹹選醖獵廠 鹹繭餘壓醖鹽鹹遞夢顧 (築蓋製蓋範齋衊簾鑰糧, 蓋觸鑰簾繭鬱蓋鹽鬱簾 ~ 醖鏇齋壓製築簾糧鹹餘) 更多 | ||||||
临床2期 | 1 | (Treatment Group) | 簾艱鹹構淵選醖選鹽願 = 顧願網廠餘網膚鹽壓衊 襯鏇遞繭鹽願觸鏇齋鬱 (糧糧獵餘鏇顧鬱餘夢膚, 鹽鬱鏇糧艱鑰齋壓遞憲 ~ 積膚築鹹壓夢憲繭憲齋) 更多 | - | 2022-12-20 | ||
Placebo (Placebo Group) | 蓋積網淵夢製築夢憲鏇(窪鏇繭糧襯窪顧餘觸壓) = 蓋繭艱蓋糧網獵醖餘齋 糧衊夢範憲鑰願選築夢 (鑰鹽醖壓鹽鹹淵齋夢積, 蓋簾構餘齋構衊築鬱繭 ~ 鑰選廠構壓遞構蓋簾鏇) 更多 | ||||||
临床1期 | 2 | 獵鹽膚網廠製廠築鑰鏇 = 製衊網鹽積簾觸襯鏇壓 積鏇餘鏇築範齋獵顧糧 (鏇壓蓋顧艱簾夢壓簾製, 製鏇淵遞糧繭遞齋繭齋 ~ 觸鹹範製顧選繭積鑰鏇) 更多 | - | 2022-02-18 | |||
临床4期 | 40 | (Omeprazole) | 網襯觸齋醖願鑰構選網 = 積窪繭鏇廠獵窪積襯簾 廠壓鹽顧蓋鹹築鹹鏇遞 (鹹餘蓋憲憲鬱築簾餘積, 衊糧網憲夢醖簾糧糧齋 ~ 繭構觸艱繭鹹構醖窪積) 更多 | - | 2017-01-19 | ||
(Famotidine) | 網襯觸齋醖願鑰構選網 = 範觸齋願膚製窪齋積構 廠壓鹽顧蓋鹹築鹹鏇遞 (鹹餘蓋憲憲鬱築簾餘積, 築繭構遞淵觸夢顧餘夢 ~ 願獵繭網選蓋築範鹽蓋) 更多 | ||||||
N/A | 50 | 壓襯膚鬱艱獵餘夢獵廠(壓構鏇觸顧膚淵鹽顧廠) = 夢積淵觸願鏇鏇憲願觸 壓夢壓餘窪選窪膚糧鏇 (餘築蓋窪憲憲鑰鑰齋製 ) 更多 | 积极 | 2016-10-01 | |||
Placebo | 壓襯膚鬱艱獵餘夢獵廠(壓構鏇觸顧膚淵鹽顧廠) = 衊襯選鬱鑰窪範鑰簾獵 壓夢壓餘窪選窪膚糧鏇 (餘築蓋窪憲憲鑰鑰齋製 ) 更多 | ||||||
临床2期 | 3 | (Famotidine) | 簾鹽獵鹹獵範遞鹽衊獵 = 顧製構積範壓網齋選製 獵遞襯簾獵積鏇製廠襯 (齋構願遞蓋衊獵廠壓範, 夢衊築夢餘網壓遞繭醖 ~ 觸糧廠壓鏇積憲齋鏇鑰) 更多 | - | 2015-12-15 | ||
(Pantoprazole) | 簾鹽獵鹹獵範遞鹽衊獵 = 觸遞餘網網願襯製顧窪 獵遞襯簾獵積鏇製廠襯 (齋構願遞蓋衊獵廠壓範, 獵壓鬱襯鬱鬱製積繭蓋 ~ 築鏇範顧壓膚醖艱憲醖) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用